Rupatadine

Generic Name: Rupatadine

Brand Names: Rupall

Drug Type: Small Molecule

Chemical Formula: C_₂₆H_₂₆ClN_₃

CAS Number: 158876-82-5

Unique Ingredient Identifier: 2AE8M83G3E

Background: Rupatadine is a dual histamine H1 receptor and platelet activating factor receptor antagonist that is used for symptomatic relief in seasonal and perennial rhinitis as well as chronic spontaneous urticaria. It was approved for marketing in Canada under the tradename Rupall and comes in tablet formulation for adult use and liquid formulation for pediatric use...

Indication: For the symptomatic relief of nasal and non-nasal symptoms of seasonal allergic rhinitis and perennial allergic rhinitis in patients 2 years of age and older . Also used for the symptomatic relief of chronic spontaneous urticaria in patients 2 years of age and older.

Associated Conditions: Allergic Rhinitis (AR), Pruritus, Urticaria

Associated Therapies: -

Clinical Trials

Pharmacokinetics and Safety of Rupatadine in Participants With Hepatic Impairment Compared to Control Participants.

Phase 1

Recruiting

Conditions: Hepatic Impairment

Interventions: Drug: Rupatadine

First Posted Date: 2024-12-16

Last Posted Date: 2024-12-16

Lead Sponsor: Noucor Health S.A.

Target Recruit Count: 44

Registration Number: NCT06736340

Locations: 🇵🇹
Centro Hospitalar De Vila Nova De Gaia Espinho, Gaia, Portugal
🇵🇹
Hospital Pedro Hispano, Matosinhos, Portugal
🇵🇹
BlueClinical Phase I, Porto, Portugal

and more 4 locations

Pharmacokinetics and Safety of Rupatadine in Participants With Renal Impairment Compared to Control Participants

Phase 1

Recruiting

Conditions: Renal Impairment

Interventions: Drug: Rupatadine

First Posted Date: 2024-11-27

Last Posted Date: 2024-12-13

Lead Sponsor: Noucor Health S.A.

Target Recruit Count: 48

Registration Number: NCT06708520

Locations: 🇵🇹
Centro Hospitalar De Vila Nova De Gaia Espinho, Gaia, Portugal
🇵🇹
Hospital Pedro Hispano, Matosinhos, Portugal
🇵🇹
Blueclinical Investigacao E Desenvolvimento Em Saude Lda., Porto, Portugal

and more 4 locations

A Comparative Study of Rupatadine 10 mg Tablets and Clarinex® 5 mg Tablets Under Fasting Conditions

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Rupatadine

First Posted Date: 2022-05-02

Last Posted Date: 2023-03-23

Lead Sponsor: J. Uriach and Company

Target Recruit Count: 45

Registration Number: NCT05356143

Locations: 🇨🇦
Pharma Medica Research Inc., Toronto, Ontario, Canada

Allergic Rhinitis Combination Pharmacotherapy Efficacy Study

Phase 4

Withdrawn

Conditions: Allergic Rhinitis

Interventions: Drug: Azelastine hydrochloride and fluticasone propionate
Drug: Fluticasone Propionate
Drug: Rupatadine

First Posted Date: 2020-10-23

Last Posted Date: 2023-10-31

Lead Sponsor: St. Paul's Sinus Centre

Registration Number: NCT04601324

Effect of Some Drugs on Rheumatoid Arithritis Activity

Phase 3

Recruiting

Conditions: Rheumatoid Arthritis

Interventions: Drug: Rupatadine
Drug: Montelukast

First Posted Date: 2018-12-10

Last Posted Date: 2018-12-10

Lead Sponsor: Sherief Abd-Elsalam

Target Recruit Count: 75

Registration Number: NCT03770923

Locations: 🇪🇬
Sherief Abd-Elsalam, Tanta, Egypt

Study to Assess Efficacy, Safety and Mechanism of Rupatadine in Cold Urticaria

Phase 2

Completed

Conditions: Cold Contact Urticaria

Interventions: Drug: Rupatadine

First Posted Date: 2012-05-25

Last Posted Date: 2014-10-15

Lead Sponsor: Charite University, Berlin, Germany

Target Recruit Count: 24

Registration Number: NCT01605487

Locations: 🇩🇪
Department of Dermatology and Allergy, Charité - Universitätsmedizin Berlin, Charitéplatz 1, Germany

Study With Rupatadine in Mosquito-Bite Allergic Adult Subjects

Phase 4

Conditions: Allergy

First Posted Date: 2005-11-24

Last Posted Date: 2005-11-24

Lead Sponsor: J. Uriach and Company

Target Recruit Count: 30

Registration Number: NCT00258141

Locations: 🇫🇮
Ulappatorin Lääkäriasema, Espoo, Finland
🇫🇮
Koskiklinikka, Tampere Lääkärikeskus, Tampere, Finland

Efficacy and Safety of Rupatadine 10 and 20 Mg in Chronic Idiopathic Urticaria

Phase 3

Terminated

Conditions: Urticaria

First Posted Date: 2005-09-20

Last Posted Date: 2005-12-23

Lead Sponsor: J. Uriach and Company

Target Recruit Count: 300

Registration Number: NCT00199251

Evaluation of Possible Effects on the QT/ QTc Interval of Rupatadine in Healthy Volunteers

Phase 1

Completed

Conditions: Human Experimentation (Human Volunteers)

First Posted Date: 2005-09-20

Last Posted Date: 2005-12-15

Lead Sponsor: J. Uriach and Company

Target Recruit Count: 160

Registration Number: NCT00199225

Locations: 🇪🇸
Centre de Investigació de Medicaments-Intitut de Recerca-Hospital de la Santa Creu i Sant Pau, Barcelona, Spain

Comparative Effects of Rupatadine 10 mg, Hydroxyzine 50 mg and Placebo on Actual Driving Performance

Phase 4

Terminated

Conditions: Healthy

First Posted Date: 2005-09-13

Last Posted Date: 2006-10-20

Lead Sponsor: J. Uriach and Company

Target Recruit Count: 20

Registration Number: NCT00162786

Locations: 🇳🇱
Brain and Behaviour Institute, Maastricht, Netherlands

Prev
1
Next

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy